Form 4: Fulcrum Therapeutics Director Sells 15,000 Shares

Fulcrum Therapeutics Director Robert J. Gould sold 15,000 shares of common stock for a weighted average price of $11.8726, reducing his direct beneficial ownership to 469,864 shares.

Summary

• Robert J. Gould, a Director of Fulcrum Therapeutics, Inc. (FULC), reported a sale of common stock.
• On January 2, 2026, Gould sold 15,000 shares of Fulcrum Therapeutics common stock.
• The shares were sold at a weighted average price of $11.8726 per share.
• The sales occurred in multiple transactions with prices ranging from $10.60 to $11.33.
• Following this transaction, Gould directly beneficially owns 469,864 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2025.

Sentiment

Score: 4

Explanation: While insider selling can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 plan, which mitigates the immediate negative interpretation. The director still retains a significant number of shares.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on recent non-public information.

Negatives

• A director selling shares can sometimes be perceived negatively by the market, suggesting a lack of confidence, even if pre-planned.
• The transaction reduces the director's direct beneficial ownership in the company.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• Reduced alignment of the director's personal financial interests with those of common shareholders due to decreased ownership.

Future Outlook

NA

Industry Context

Insider transactions, particularly sales, are closely watched by investors as they can signal management's perception of the company's future prospects. However, sales made under a Rule 10b5-1 plan are generally viewed with less concern as they are pre-scheduled and not typically indicative of new, negative information.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative, though the 10b5-1 plan reduces the severity. Could lead to minor short-term price volatility.

Key Dates

Recommendation

The sale by a director, even under a 10b5-1 plan, warrants attention. However, without additional company-specific news or financial updates, this single transaction is not a strong enough signal to recommend a 'buy' or 'sell'. The pre-planned nature suggests it's for personal financial planning rather than a reaction to new company developments. Investors should 'hold' and monitor future company performance and additional insider activity.

Keywords

Fulcrum Therapeutics, FULC, Insider Trading, Form 4, Stock Sale, Director Transaction, Robert J. Gould, 10b5-1 Plan, Beneficial Ownership